Rituximab and Interleukin-2 in Treating Patients With Relapsed or Refractory Intermediate- or High-Grade Non-Hodgkin's Lymphoma
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Hoag Memorial Hospital Presbyterian
Fred Hutchinson Cancer Center